ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.

What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia and Genecast Biotechnology Partner to Launch MammaPrint and BluePrint in China
For the first time, early-stage breast cancer patients and their physicians in China can access clinically validated and prospectively proven tests for breast cancer risk of recurrence and molecular subtyping IRVINE, CALIF., U.S., AMSTERDAM, NETHERLANDS Read More
US Oncology Research Joins Agendiaโs FLEX Big Data Initiative, Accelerating Diagnostic Discoveries in Breast Cancer and Enabling Precision Oncology
Dataset of up to 10,000 full genome profiles matched with complete clinical data will provide representative resource for breast cancer research IRVINE, CALIF., U.S., THE WOODLANDS, TEXAS, U.S., and AMSTERDAM, NETHERLANDS (23 August 2018) โ Read More
An Update on Agendiaโs Precision Oncology Achievements in Breast Cancer
As we close out the first half of 2018, Iโd like to take a moment to reflect on Agendiaโs recent achievements as a global leader in precision oncology and provide an update on forward-looking expansions Read More
Agendia Secures $35 Million Investment from Funds Managed by Athyrium Capital Management to Support Expanded Commercial Footprint in Rapidly Growing Markets and New Research Collaborations
IRVINE, CA and AMSTERDAM, NETHERLANDS โ 25 July 2018 โ Agendia, Inc., a world leader in precision oncology, today announced the completion of $35 million in financing from investment funds managed by Athyrium Capital Management Read More